Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPA1 | P27694 | 7/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PPP1CA | P62136 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL570061 | 0.85 | RPA1 (0.63) | RPA1SMN1; SMN2MCL1ALDH1A1PPP1CA | |
| SCHEMBL2565035 | 0.84 | RPA1 (0.66) | RPA1SMN1; SMN2PPP1CAL3MBTL1MEN1 | |
| SCHEMBL1413877 | 0.84 | KMT2A (0.58) | RPA1SMN1; SMN2SMPD1ALDH1A1PPP1CA | |
| SCHEMBL22578393 | 0.83 | TP53 (0.54) | SMN1; SMN2SMPD1MEN1KMT2ARXFP1 | |
| SCHEMBL2203114 | 0.83 | RPA1 (0.51) | RPA1MCL1ALDH1A1PPP1CAMEN1 | |
| SCHEMBL20430981 | 0.83 | BAZ2B (0.54) | SMPD1MEN1KMT2ARXFP1GRM5 | |
| SCHEMBL20656279 | 0.82 | RPA1 (0.47) | RPA1SMN1; SMN2ALDH1A1PPP1CAL3MBTL1 | |
| SCHEMBL4746928 | 0.81 | MDM2 (0.58) | RPA1SMN1; SMN2MCL1ALDH1A1PPP1CA | |
| SCHEMBL4688189 | 0.81 | NR1H4 (0.61) | RPA1SMN1; SMN2ALDH1A1PPP1CAL3MBTL1 | |
| SCHEMBL14758678 | 0.81 | KMO (0.49) | RPA1SMN1; SMN2ALDH1A1PPP1CAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685113-B1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1685113-B1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| EP-1685113-A1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005049578-A1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | PPARD, PPARA, PPARG | RPA1 3262/4885PTPN1 2086/4885SMN1; SMN2 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.